Elliott M J, Feldmann M, Maini R N
Kennedy Institute of Rheumatology, London, U.K.
Int J Immunopharmacol. 1995 Feb;17(2):141-5. doi: 10.1016/0192-0561(94)00092-3.
Tumor necrosis factor alpha (TNF alpha) is a cytokine with many biological functions of relevance to inflammatory disease. Although only one of several inflammatory mediators produced in abundance in rheumatoid arthritis (RA), experimental data suggest that it is in a dominant position within a cytokine hierarchy and is therefore a prime target for directed immunotherapy in this disease. We have targeted TNF alpha in vivo using a chimerised monoclonal anti-TNF alpha antibody and have now demonstrated beneficial responses to treatment in three different clinical trials. The results confirm that TNF alpha is of central importance in the inflammatory process in RA and define a new treatment strategy in this disease.
肿瘤坏死因子α（TNFα）是一种具有许多与炎症性疾病相关生物学功能的细胞因子。虽然它只是类风湿关节炎（RA）中大量产生的几种炎症介质之一，但实验数据表明，它在细胞因子层级中处于主导地位，因此是该疾病定向免疫治疗的主要靶点。我们使用嵌合单克隆抗TNFα抗体在体内靶向TNFα，并且现已在三项不同的临床试验中证明了治疗产生的有益反应。结果证实TNFα在RA的炎症过程中至关重要，并确定了该疾病的一种新治疗策略。
